Table 5.

Phase II trials with HER2 inhibitors

Drug	Molecular alteration	n	ORR%	PFS (mo)	OS (mo)
Dacomitinib[44]	HER2 mutant	26	12	NR	NR
	HER2-amplified	4	0	NR	NR
Neratinib + Trastuzumab[46]	HER2 mutant	52	17	4	10.2
Neratinib + Temsirolimus[46]	HER2 mutant	43	19	4	15.1
Pyrotinib[47]	HER2 mutant	60	30	6.9	14.4
Poziotinib[48]	HER2 mutant	90	28	5.5	NR
Trastuzumab emtansine[49]	IHC 2+	29	0	2.6	12.2
	IHC 3+	20	20	2.7	15.3
Trastuzumab deruxtecan[49]	HER-2 mutant	42	61.9	NR	NR
Trastuzumab deruxtecan[49]	IHC 2+	39	25.6	5.4	11.3
	IHC 3+	10	20

ORR: Overall response rate; PFS: Progression free survival; OS: Overall survival; NR: Not reported.